Overview

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
This trial is a Phase Ib/II study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and AK104 with or without chemothorapy in subjects with advanced NSCLC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Akeso
Treatments:
Docetaxel
Paclitaxel
Pemetrexed